⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30937183 | 1.00 | — | — | |
| SCHEMBL28293051 | 0.87 | NOS3 (0.42) | — | |
| Formic Acid SCHEMBL28079694 | 0.87 | NAPRT (0.46) | — | |
| SCHEMBL5790425 | 0.77 | ALDH1A1 (0.61) | — | |
| SCHEMBL196235 | 0.72 | CYP2A6 (0.61) | — | |
| SCHEMBL29365135 | 0.72 | — | — | |
| SCHEMBL255507 | 0.72 | — | — | |
| SCHEMBL29924154 | 0.72 | CYP2A6 (0.61) | — | |
| SCHEMBL29457380 | 0.72 | — | — | |
| SCHEMBL65397 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 902 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4304713-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | claimed |
| CN-114361590-B | Electrolyte additive for lithium ion battery, electrolyte and lithium ion battery | 松山湖材料实验室 | 2023-07-25 | — | — | CN | claimed |
| EP-4025572-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | claimed |
| CN-114361590-A | Lithium ion battery electrolyte additive, electrolyte and lithium ion battery | 松山湖材料实验室 | 2022-04-15 | — | — | CN | claimed |
| WO-2021046447-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | claimed |
| US-20210070744-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | claimed |
| EP-3050873-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-09-13 | — | — | EP | claimed |
| CN-106432222-A | 8-chloro-1-cyclopropyl-7-fluorine-9-methyl-4-oxygen-4-hydrogen-quinolizine-3-carboxylic ester and preparation method thereof | 丹诺医药(苏州）有限公司 | 2017-02-22 | — | — | CN | claimed |
| EP-3050873-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-08-03 | — | — | EP | claimed |
| EP-2651893-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-03-30 | — | — | EP | claimed |
| CN-103429589-A | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG | 2013-12-04 | — | — | CN | claimed |
| EP-2651893-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-23 | — | — | EP | claimed |
| US-8450367-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-05-28 | — | — | US | claimed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | claimed |
| WO-2012082566-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | claimed |
| WO-2006026760-A2 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-09 | — | — | WO | claimed |
| EP-0495939-A4 | SEQUENTIAL C-TERMINAL DEGRADATION OF PEPTIDES AND PROTEINS | — | 1992-11-25 | — | — | EP | claimed |
| EP-0495939-A1 | SEQUENTIAL C-TERMINAL DEGRADATION OF PEPTIDES AND PROTEINS. | HOPE CITY (US) | 1992-07-29 | — | — | EP | claimed |
| WO-1992003737-A1 | SEQUENTIAL C-TERMINAL DEGRADATION OF PEPTIDES AND PROTEINS | CITY OF HOPE (US) | 1992-03-05 | — | — | WO | claimed |